Secretory effects of ATP on nontransformed dog pancreatic duct epithelial cells.
Extracellular triphosphate nucleotides, such as ATP, may regulate various cellular functions through specific cell surface receptors. We examine in this report the different secretory effects of ATP and analogs on nontransformed dog pancreatic duct epithelial cells (PDEC). We observed that 1) ATP, UTP, adenosine 5'-O-(3-thiotriphosphate), and, to a lesser extent, beta, gamma-methylene-ATP, but not adenosine, stimulated 125I- efflux from PDEC, suggesting a primary role for P2Y2 receptors, 2) ATP-stimulated 125I- efflux was inhibited by 5-nitro-2-(3-phenylpropylamino)benzoic acid, diphenylamine-2-carboxylate, and DIDS, suggesting mediation through Ca2+-activated Cl- channels, 3) ATP stimulated an 86Rb+ efflux sensitive to BaCl2 and charybdotoxin, thus likely occurring through Ca2+-activated K+ channels, 4) serosal or luminal addition of UTP activated apical Cl- conductance and basolateral K+ conductance when nystatin-permeabilized PDEC were studied in an Ussing chamber, suggesting the expression of P2Y2 receptors on both sides of the cell, 5) ATP stimulated mucin secretion, and 6) ATP increases intracellular Ca2+ concentration ([Ca2+]i). In conclusion, ATP and UTP interact with P2Y2 receptors on nontransformed PDEC to increase [Ca2+]i, stimulate mucin secretion, and activate ion conductances; these findings have implications for pancreatic exocrine function in both health and disease, such as cystic fibrosis.
Nguyen
T D
TD
Department of Medicine, University of Washington, and Veterans Affairs Puget Sound Health Care System, Seattle, Washington 98108, USA.
Moody
M W
MW
Savard
C E
CE
Lee
S P
SP
D017878:4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid / Q000494:pharmacology; D000255:Adenosine Triphosphate / Q000031:analogs & derivatives / Q000494:pharmacology*; D000818:Animals; D017609:Barium Compounds / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism*; D002121:Calcium Channel Blockers / Q000494:pharmacology; D002478:Cells, Cultured; D018999:Charybdotoxin / Q000494:pharmacology; D002712:Chlorides / Q000494:pharmacology; D004285:Dogs; D004847:Epithelial Cells / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D007700:Kinetics; D009077:Mucins / Q000096:biosynthesis* / Q000378:metabolism; D009579:Nitrobenzoates / Q000494:pharmacology; D010183:Pancreatic Ducts / Q000166:cytology / Q000502:physiology*; D015221:Potassium Channels / Q000187:drug effects / Q000502:physiology; D012414:Rubidium Radioisotopes / Q000493:pharmacokinetics; D014544:Uridine Triphosphate / Q000494:pharmacology; D062367:ortho-Aminobenzoates / Q000494:pharmacology
D017609:Barium Compounds; D002121:Calcium Channel Blockers; D002712:Chlorides; D009077:Mucins; D009579:Nitrobenzoates; D015221:Potassium Channels; D012414:Rubidium Radioisotopes; D062367:ortho-Aminobenzoates; C024986:barium chloride; D018999:Charybdotoxin; C085057:4-nitro-2-(3-phenylpropylamino)benzoate; D000255:Adenosine Triphosphate; C001209:fenamic acid; D017878:4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; D002118:Calcium; D014544:Uridine Triphosphate